The combined use of PRKDC and CDK4 inhibitors most significantly decreased the proliferation of PDC_PRKDCAmp&CDK4Amp cells, demonstrating that PRKDC could enhance the ability of CDK4 to promote tumor cell proliferation in the S-III subtype (Fig. 4p). Here, PRKDC is linked to neoplasm.